Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H29NO2.C10H8O3S.H2O |
Molecular Weight | 565.72 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.OS(=O)(=O)C1=CC2=C(C=CC=C2)C=C1.CCC(=O)O[C@](CC3=CC=CC=C3)([C@@H](C)CN(C)C)C4=CC=CC=C4
InChI
InChIKey=GBKONKCASNNUQD-ATVRCVQASA-N
InChI=1S/C22H29NO2.C10H8O3S.H2O/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19;11-14(12,13)10-6-5-8-3-1-2-4-9(8)7-10;/h6-15,18H,5,16-17H2,1-4H3;1-7H,(H,11,12,13);1H2/t18-,22+;;/m0../s1
Molecular Formula | C10H8O3S |
Molecular Weight | 208.234 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C22H29NO2 |
Molecular Weight | 339.4712 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.drugbank.ca/drugs/DB06793
Sources: https://www.drugbank.ca/drugs/DB06793
LEVOPROPOXYPHENE is an antitussive drug, one of enantiomer of propoxyphene. Pdropoxyphene is an analgesic in the opioid category, patented in 1955 and manufactured by Eli Lilly and Company. Pdropoxyphene is intended to treat mild pain and also has antitussive (cough suppressant) and local anaesthetic effects.
Originator
Approval Year
Doses
Dose | Population | Adverse events |
---|---|---|
100 mg 6 times / day multiple, oral Highest studied dose Dose: 100 mg, 6 times / day Route: oral Route: multiple Dose: 100 mg, 6 times / day Sources: |
unhealthy, adult n = 50 Health Status: unhealthy Condition: nonproductive cough Age Group: adult Sex: M+F Population Size: 50 Sources: |
Disc. AE: Nausea... AEs leading to discontinuation/dose reduction: Nausea Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Nausea | Disc. AE | 100 mg 6 times / day multiple, oral Highest studied dose Dose: 100 mg, 6 times / day Route: oral Route: multiple Dose: 100 mg, 6 times / day Sources: |
unhealthy, adult n = 50 Health Status: unhealthy Condition: nonproductive cough Age Group: adult Sex: M+F Population Size: 50 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no [Activation >10 uM] | ||||
no [Activation >10 uM] | ||||
no [Activation >10 uM] | ||||
yes [Activation 5.01187 uM] | ||||
yes [Activation 7.94328 uM] |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4815955
The disposition of propoxyphene and its major biotransformation product norpropoxyphene was studied in normal subjects following a single 130 mg oral dose.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:15:54 GMT 2023
by
admin
on
Fri Dec 15 17:15:54 GMT 2023
|
Record UNII |
KK9590R73S
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66917
Created by
admin on Fri Dec 15 17:15:54 GMT 2023 , Edited by admin on Fri Dec 15 17:15:54 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5667-69-6
Created by
admin on Fri Dec 15 17:15:54 GMT 2023 , Edited by admin on Fri Dec 15 17:15:54 GMT 2023
|
SUPERSEDED | |||
|
100000086126
Created by
admin on Fri Dec 15 17:15:54 GMT 2023 , Edited by admin on Fri Dec 15 17:15:54 GMT 2023
|
PRIMARY | |||
|
55557-30-7
Created by
admin on Fri Dec 15 17:15:54 GMT 2023 , Edited by admin on Fri Dec 15 17:15:54 GMT 2023
|
PRIMARY | |||
|
KK9590R73S
Created by
admin on Fri Dec 15 17:15:54 GMT 2023 , Edited by admin on Fri Dec 15 17:15:54 GMT 2023
|
PRIMARY | |||
|
402519
Created by
admin on Fri Dec 15 17:15:54 GMT 2023 , Edited by admin on Fri Dec 15 17:15:54 GMT 2023
|
PRIMARY | RxNorm | ||
|
C90774
Created by
admin on Fri Dec 15 17:15:54 GMT 2023 , Edited by admin on Fri Dec 15 17:15:54 GMT 2023
|
PRIMARY | |||
|
7247-77-0
Created by
admin on Fri Dec 15 17:15:54 GMT 2023 , Edited by admin on Fri Dec 15 17:15:54 GMT 2023
|
SUPERSEDED | |||
|
16051927
Created by
admin on Fri Dec 15 17:15:54 GMT 2023 , Edited by admin on Fri Dec 15 17:15:54 GMT 2023
|
PRIMARY | |||
|
SUB02912MIG
Created by
admin on Fri Dec 15 17:15:54 GMT 2023 , Edited by admin on Fri Dec 15 17:15:54 GMT 2023
|
PRIMARY | |||
|
DTXSID901014588
Created by
admin on Fri Dec 15 17:15:54 GMT 2023 , Edited by admin on Fri Dec 15 17:15:54 GMT 2023
|
PRIMARY | |||
|
CHEMBL1738990
Created by
admin on Fri Dec 15 17:15:54 GMT 2023 , Edited by admin on Fri Dec 15 17:15:54 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ANHYDROUS->SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |